SLC5A2 and chronic kidney disease: In a meta-analysis of these trials, SGLT2 inhibitors reduced the incidence of the composite renal outcome of worsening renal function (doubling of serum creatinine accompanied by an eGFR of ≤45 mL/min/1.73 m2), end-stage renal disease (ESRD) defined as eGFR <15 mL/min/1.73 m2) or renal death (defined as: “any adjudicated non-CV death event where the adjudication committee assigned a renal proximate cause is considered a renal death”) by 45% (HR, 0.55; 95%CI, 0.48–0.64) [88].